High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: L773:1078 0432 OR L773:1557 3265 > High progesterone r...

Stendahl, MariaLund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups,Department of Laboratory Medicine, Lund University, Malmö University Hospital, S-205 02 Malmö, Sweden, Department of Medicine, Ryhov Regional Hospital, Jönköping, Sweden (författare)

High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients

Artikel/kapitelEngelska2006

Förlag, utgivningsår, omfång ...

2006
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:liu-50166
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-50166URI
https://doi.org/10.1158/1078-0432.CCR-06-0248DOI
https://lup.lub.lu.se/record/160169URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Purpose: Tamoxifen has long been the drug of choice in adjuvant endocrine therapy of steroid hormone receptor-positive breast cancer, and it still remains important due to its well-documented beneficial effect. Hormone receptor status is often reported as "positive" or "negative" using 10% positive nuclei as a cutoff. In this study, we aimed to assess whether a further subclassification of hormone receptor status could enhance the treatment predictive value. Experimental Design: The immunohistochemical expression of estrogen receptor (ER) and progesterone receptor (PR) was quantified in tissue microarrays with tumors from 500 premenopausal breast cancer patients previously included in a randomized trial of adjuvant tamoxifen compared with an untreated control group. Results: Our findings show a gradually increasing tamoxifen effect in tumors with >10% ER-positive nuclei. However, when analyzing tamoxifen response according to various PR fractions, we found that it was primarily patients with tumors showing >75% PR-positive nuclei that responded to tamoxifen treatment, with an improved recurrence-free [relative risk, 0.42 (0.25-0.70), P = 0.001] as well as overall [relative risk, 0.49 (0.28-0.84), P = 0.010] survival. Conclusions: Adjuvant tamoxifen improved recurrence-free and overall survival for premenopausal patients with tumors showing >75% PR-positive nuclei. No effect could be shown in tumors with fewer PR-positive nuclei. The PR was a stronger predictor of treatment response than the ER. Based on these findings, we suggest the implementation of a fractioned rather than dichotomized immunohistochemical evaluation of hormone receptors in clinical practice, possibly with greater emphasis on the PR than the ER. © 2006 American Association for Cancer Research.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
MEDICINE
MEDICIN

Biuppslag (personer, institutioner, konferenser, titlar ...)

Rydén, LisaLund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Rydén, L., Department of Laboratory Medicine, Lund University, Malmö University Hospital, S-205 02 Malmö, Sweden(Swepub:lu)pat-lry (författare)
Nordenskjöld, BoÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US(Swepub:liu)bono64 (författare)
Jonsson, P.E.Jönsson, P.E., Department of Surgery, Helsingborg Hospital, Helsingborg, Sweden (författare)
Landberg, GöranLund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups,Department of Laboratory Medicine, Lund University, Malmö University Hospital, S-205 02 Malmö, Sweden(Swepub:lu)pat-gla (författare)
Jirström, KarinLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Jirström, K., Department of Laboratory Medicine, Lund University, Malmö University Hospital, S-205 02 Malmö, Sweden(Swepub:lu)pat-kji (författare)
Patologi, MalmöForskargrupper vid Lunds universitet (creator_code:org_t)

Sammanhörande titlar

Ingår i:Clinical Cancer Research12:15, s. 4614-46181078-04321557-3265

Internetlänk

Hitta via bibliotek

Clinical Cancer Research (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Stendahl, Maria; Rydén, Lisa; Nordenskjöld, Bo; Jonsson, P.E.; Landberg, Göran; Jirström, Karin

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Clinical Cancer ...

Av lärosätet: Linköpings universitet; Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se